{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-25-004115","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.126766+00:00","generated_at":"2026-05-17T00:39:22.578706+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prelude gets $60M from Incyte for JAK2V617F option; pauses SMARCA2; CMO resigns","bullets":["Incyte receives exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program for $100M exercise price, plus up to $775M milestones and single-digit royalties.","Prelude receives $60M in capital: $35M upfront plus $25M equity investment (6.25M shares at $4.00 each).","Company pauses clinical development of SMARCA2 degrader program to prioritize JAK2V617F and KAT6A degrader programs.","President and CMO Jane Huang resigns; board member Dr. Victor Sandor steps in to oversee clinical development.","Cash runway extended into 2027 (potentially 2028 if Incyte exercises option); preliminary cash ~$52M as of Oct 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-25-004115","json":"https://secwatch.observer/filing/0000929638-25-004115.json","markdown":"https://secwatch.observer/filing/0000929638-25-004115.md","text":"https://secwatch.observer/filing/0000929638-25-004115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/0000929638-25-004115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:39:22.578706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d46112db9ca8ed51b4fb4f998adcedb1e6443dd","claim":"Prelude Therapeutics Inc issued 6,250,000 shares of common stock to Incyte Corporation for $4.00 per share for a total of $25 million.","evidence_excerpt":"the Company entered into a securities purchase agreement with Incyte (the \"Securities Purchase Agreement\"), pursuant to which Incyte has agreed to purchase 6,250,000 shares (the \"Shares\") of the Company’s non-voting common stock (the \"Non-Voting Common Stock\") at a price of $4.00 per share for a total of $25 million.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/0000929638-25-004115-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"6,250,000 shares"},{"label":"Purchaser","value":"Incyte Corporation"},{"label":"Consideration","value":"$4.00 per share for a total of $25 million"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}